US medical device company Autonomix Medical, Inc. (NASDAQ: AMIX) announced on Thursday that it has been granted a patent from the United States Patent and Trademark Office covering systems, devices, and methods that sense autonomic and cardiac signals, map targets, and deliver therapy with closed-loop feedback.

The technology is designed to enable feedback-driven neuromodulation, denervation, and ablation of cardiac tissues.

Chief Executive Officer Brad Hauser said the patent No. 12,369,852, titled Controlled and Precise Treatment of Cardiac Tissues, reinforces the company's intellectual property portfolio and supports its strategy to provide alternatives to systemic beta-receptor blockade, which often causes unwanted side effects.

The technology is designed to deliver precision therapies in cardiology, including renal denervation for hypertension, and arrhythmia management. The patent also highlights applications across ischemia and angina, coronary spasm, myocardial infarction risk modulation, and plaque or inflammation modulation.

Autonomix holds more than 120 issued and pending patent applications globally, building a comprehensive intellectual property portfolio in nerve-sensing and modulation. The company's platform technology has potential applications across multiple therapeutic areas, including cardiology, interventional pain management, pulmonary disorders, and gastrointestinal conditions.